Bleeding Events Associated With Continuing Antithrombotic Therapy During Transrectal Ultrasound‐Guided Prostate Biopsy: A Propensity Score‐Matched Analysis
International Journal of Urology · 2026
DOI: 10.1111/iju.70580 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Urology, 2026. Verfasst von Kenichi Hata und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Shonan Keiiku Hospital, Fujisawa, Kanagawa, Japan. Hauptthemen laut MEDLINE: Prostate, Image-Guided Biopsy, Prostatic Neoplasms, Fibrinolytic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objectives
To evaluate the association between antithrombotic continuation and the frequency and severity of bleeding events during transrectal ultrasound‐guided prostate biopsies.
Methods
This retrospective cohort study involved 1248 patients who underwent transrectal ultrasound‐guided prostate biopsy between April 2018 and December 2024. Patients were grouped into antithrombotic(+) (continued therapy) or antithrombotic(−) (no therapy). The groups were matched 1:1 using propensity scores based on patient demographics.
Results
Propensity score matching yielded 162 patients per group. Mild and severe hematuria rates were comparable between the antithrombotic(+) and antithrombotic(−) groups (80.9% and 1.9% vs. 72.8% and 2.5%), with overall rectal bleeding occurring in 29.6% and 29.0%, respectively. Hematospermia rates did not differ significantly. In the unmatched direct‐acting oral anticoagulant cohort, severe rectal bleeding occurred in three patients (5.7%). Multivariate analysis identified diabetes mellitus (odds ratio, 3.47, 95% confidence interval, 1.10–10.96; p = 0.034) and biopsy core number (odds ratio, 0.39, 95% confidence interval, 0.21–0.74; p = 0.004) as independent predictors of severe bleeding events.
Conclusions
Transrectal ultrasound‐guided prostate biopsy was generally safe without antithrombotic discontinuation, with no significant increase in bleeding events. Caution is warranted when continuing direct‐acting oral anticoagulants, particularly in patients with risk factors for bleeding, such as diabetes mellitus.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Shonan Keiiku Hospital, Fujisawa, Kanagawa, Japan.
- Department of Urology, Atsugi City Hospital, Atsugi, Kanagawa, Japan.
- Department of Urology, Jikei University School of Medicine, Minato, Tokyo, Japan.
ORCID-Profile: Takahiro Kimura
Zitieren
APA
Hata, K., Goto, Y., Hashimoto, M., Okamoto, M., Takahashi, Y., Takiguchi, Y., Saito, S., Iwamoto, Y., Kawaharada, A., Enei, Y., Sakanaka, K., Takahashi, K., Hisakane, A., Yamazaki, T., Yasue, K., Aoki, S., Kasai, K., Ishii, G., & Kimura, T. (2026). Bleeding Events Associated With Continuing Antithrombotic Therapy During Transrectal Ultrasound‐Guided Prostate Biopsy: A Propensity Score‐Matched Analysis. International Journal of Urology. https://doi.org/10.1111/iju.70580
Vancouver
Hata K, Goto Y, Hashimoto M, Okamoto M, Takahashi Y, Takiguchi Y, et al. Bleeding Events Associated With Continuing Antithrombotic Therapy During Transrectal Ultrasound‐Guided Prostate Biopsy: A Propensity Score‐Matched Analysis. International Journal of Urology. 2026. doi:10.1111/iju.70580
BibTeX
@article{Hata2026,
author = {Hata, Kenichi and Goto, Yuma and Hashimoto, Masaki and Okamoto, Maria and Takahashi, Yusuke and Takiguchi, Yuki and Saito, Shun and Iwamoto, Yuya and Kawaharada, Ayaka and Enei, Yuki and Sakanaka, Keigo and Takahashi, Kazuhiro and Hisakane, Akira and Yamazaki, Taisuke and Yasue, Keiji and Aoki, Soichiro and Kasai, Kanako and Ishii, Gen and Kimura, Takahiro},
title = {Bleeding Events Associated With Continuing Antithrombotic Therapy During Transrectal Ultrasound‐Guided Prostate Biopsy: A Propensity Score‐Matched Analysis},
journal = {International Journal of Urology},
year = {2026},
doi = {10.1111/iju.70580}
}
EUVIMED